CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|15|8|808-817

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.15, Iss.8, 2014-10, pp. : 808-817

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs

By Ohno Yoshiyuki   Hisaka Akihiro   Suzuki Hiroshi  

Clinical Pharmacokinetics, Vol. 46, Iss. 8, 2007-01 ,pp. : 681-696

Adis International

Access to resources Recommend Favorite

Phosphorylation and protein–protein interactions in PXR-mediated CYP3A repression

By Pondugula Satyanarayana R   Dong Hanqing   Chen Taosheng  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 861-873

Informa Healthcare

Access to resources Recommend Favorite

Trazodone label now warns of potential interactions via CYP3A4

By  

Inpharma, Vol. 1, Iss. 1438, 2004-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors

By Molden Espen  

Drug Safety, Vol. 31, Iss. 7, 2008-01 ,pp. : 587-596

Adis International

Access to resources Recommend Favorite

An Evaluation of Ondansetron Binding Interactions with Human Cytochrome P450 Enzymes CYP3A4 and CYP2D6

By  

Drug Metabolism Letters, Vol. 4, Iss. 1, 2010-01 ,pp. : 25-30

Bentham Science Publishers

Access to resources Recommend Favorite